Apnimed filed for an initial public offering and plans to list on the Nasdaq Global Market under the ticker “APMD.” The late-stage pharmaceutical company is developing an oral therapy for obstructive sleep apnea (OSA) and has submitted an NDA to the FDA. BofA Securities, Evercore ISI, Cantor and LifeSci Capital are listed as joint bookrunners.

Business Description

Apnimed is a late‑stage clinical pharmaceutical company focused on developing oral therapies for sleep‑related breathing disorders. Its lead and only clinical asset, Oxnimbi (AD109), is a fixed‑dose combination of aroxybutynin (a novel anti‑muscarinic) and atomoxetine (a selective norepinephrine reuptake inhibitor) intended to address neuromuscular dysfunction in obstructive sleep apnea (OSA). The drug is designed as a once‑daily, at‑bedtime pill to improve upper airway muscle activity during sleep.

Oxnimbi has completed two Phase 3 trials (SynAIRgy and LunAIRo) enrolling approximately 1,300 adults with mild to severe OSA, demonstrating statistically significant reductions in apnea‑hypopnea index (AHI) and hypoxic burden (HB) versus placebo, with a generally well‑tolerated profile. The company submitted a New Drug Application to the FDA in April 2026 and holds Fast Track designation. If approved, Apnimed plans a focused U.S. launch and believes Oxnimbi could complement existing treatments (e.g., PAP, GLP‑1s in obese patients) and open an oral pathway for millions of diagnosed but untreated patients.

Market Overview

  • Total addressable market: About 80 million adults in the U.S. and ~1 billion people worldwide with OSA.
  • Market growth: Roughly 3 million newly diagnosed OSA patients annually in the U.S.; 23 million diagnosed patients active in the healthcare system over 2019–2024.
  • Market position: Aims to be the first oral therapy addressing neuromuscular dysfunction in OSA with once‑daily dosing.
  • Key competitors: PAP device makers (ResMed, Philips Respironics), Inspire Medical (hypoglossal nerve stimulation), GLP‑1/GIP drugs (e.g., tirzepatide) for obese moderate‑to‑severe OSA, and other pharma developers (Bayer, Incannex, Mosanna).
  • Industry trends: Shift from device-centric care; potential expansion from sleep specialists to primary care; rising awareness via at‑home testing and wearables; GLP‑1 interest limited to certain obese OSA populations.

Operational Metrics

  • Customers: Pre‑commercial; no product sales to date
  • Locations: Headquarters in Cambridge, Massachusetts
  • Geographic presence: Clinical operations primarily in the United States; Phase 3 SynAIRgy included sites in the United States and Canada
  • Partnerships: Clinical services with Syneos; prior joint venture with Shionogi (divested in April 2026); Fast Track designation from FDA
  • Orders/GMV: Not applicable (pre‑revenue product pipeline)
  • Other key metrics: Approximately 1,300 patients enrolled across two Phase 3 registrational trials; 65 full‑time employees as of March 31, 2026; intellectual property spans 26 patent families with multiple issued U.S. and foreign patents

Financials Highlights

  • Revenue (current): Q1 2026 revenue (related party): $84.8 million
  • Revenue growth: Increase from $3.1 million in Q1 2025 (≈2,609%)
  • Net income: Q1 2026 net income: $67.7 million; FY 2025 net loss: $128.2 million

Management

  • Kevin R. Lind, Chief Executive Officer - Former CEO and co‑founder of Longboard Pharmaceuticals; prior roles at Arena Pharmaceuticals and TPG.
  • Michael Kelly, Chief Financial Officer - More than 20 years in healthcare investment banking, including Cantor Fitzgerald, RBC, Barclays and Citigroup.
  • Dennis P. Molnar, President & Chief Operating Officer - 25+ years of biopharma leadership; former CEO of Paratek Pharmaceuticals; pharma and consulting experience.
  • John Cronin, M.D., Chief Medical Officer - Sleep medicine physician; former CMO at Philips Respironics; prior roles at BetterNight and Scripps Clinic Sleep Center.
  • Graham Goodrich, Chief Commercial Officer - Led U.S. launches and portfolio strategy at Biohaven/Pfizer; prior commercial leadership at Boehringer Ingelheim.
  • Barry Wohl, Chief Business Officer - Co‑founder; strategy and alliance roles at Macrolide, IMS/IQVIA; prior device and pharma experience.
  • Steven Spector, J.D., Chief Legal Officer and Head of Corporate Affairs - 25+ years in biotech legal and BD leadership; former EVP and General Counsel at Arena and Longboard.

IPO Structure

  • Issuer: Apnimed, Inc.
  • Filing date: July 10, 2026
  • Proposed ticker: APMD
  • Exchange: Nasdaq Global Market
  • Lead underwriters: BofA Securities; Evercore ISI; Cantor; LifeSci Capital
  • Use of proceeds: Fund the FDA approval process and, if approved, the U.S. commercial launch of Oxnimbi; remaining proceeds for R&D, working capital, and general corporate purposes.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.